Cabergoline for prolactinoma (dopamine agonist, first-line)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CABERGOLINE |
|---|
| ID | REG-CABERGOLINE-PROLACTINOMA |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-CNS-2025 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1). Cabergoline is first-line for prolactinoma per the Disease narrative (preferred over bromocriptine). Bromocriptine regimen not separately authored in this pass — see DIS-PITUITARY-ADENOMA proposal notes.
Used By
Indication
IND-PITUITARY-ADENOMA-1L-PROLACTINOMA-CABERGOLINE- IND-PITUITARY-ADENOMA-1L-PROLACTINOMA-CABERGOLINE